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Abstract
Rationale: Data on anti-HCV therapy in patients on dialysis is still evolving. Sofosbuvir is mainly eliminated through the renal route
and there is controversy about its use in these patients.
Patient concerns: We describe a 53-year-old male patient with HCV genotype 3 and human immunodeﬁciency type 1 (HIV)
infection on chronic dialysis. HIV infection was diagnosed in 1987 and since July 2007 the patient was compliant with his antiretroviral
therapy (ART) and had an undetectable plasma HIV viral load on all follow-up measurements. The patient was known to have HCV
infection since 1997 but has never been treated for chronic hepatitis C. Because of progressive renal impairment dialysis started in
2005.
Diagnosis: Before anti-HCV treatment commenced the patient liver transient elastography (FibroScan) indicated F3 ﬁbrosis
(stiffness, 11.6 kPa) and his HCV RNA viral load was 320,798 IU/mL (Abbott RealTime HCV assay).
Intervention: Fixed dose combination of sofosbuvir/velpatasvir (400mg/100mg) for 11 weeks.
Outcomes: Twelve weeks after treatment cessation HCV RNAwas undetectable, hence the patient achieved a sustained virologic
response. The drugs were well tolerated and the patient did not report any side effects.
Lessons: Sofosbuvir/velpatasvir may be an option for HCV genotype 3 infection in patients coinfected with HIV on long-term
dialysis.
Abbreviations: ART = antiretroviral therapy, HCV = hepatitis C virus, HIV = human immunodeﬁciency virus, PCR = polymerase
chain reaction, RNA = ribonucleic acid, SVR12 = sustained virological response 12 weeks after treatment.
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With direct-acting antivirals, hepatitis C virus (HCV) infection
can be successfully treated in almost 100% of persons. Limited
clinical experience with the use of sofosbuvir in patients withEditor: N/A.
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1HCV genotype 1 with impaired renal function or on dialysis has
been previously reported.[1–4] The real-world longitudinal HCV-
TARGET study evaluated the use of sofosbuvir-containing
regimens in patients with mild to severe renal dysfunction and
sustained virological response 12 weeks after treatment (SVR12)
was similar in all groups (82%–83%).[5] However, in this study
only 5 patients were on dialysis, velpatasvir was not used and
none of the patients were coinfected with human immunodeﬁ-
ciency virus (HIV). Hence, data on the safety and efﬁcacy of anti-
HCV therapy in patients on dialysis is still evolving, particularly
for the treatment of HCV genotype 3 in HIV coinfected persons.2. Case report
We describe a 53-year-old HIV positive male on chronic
hemodialysis, coinfected with HCV genotype 3 who was
successfully treated for hepatitis C using the combination of
sofosbuvir/velpatasvir. The diagnosis of HIV infection was made
in 1987 and HCV infection was documented in May 1997. His
ﬁrst HCV viral load was done in April 2000, the patient had
536,000IU/mL HCV RNA (Cobas Amplicor HCVMonitor test,
v2.0, Roche Switzerland). Antiretroviral combination therapy
(ART) with stavudine, lamivudine, and indinavir was initiated in
December 1999. However, the patient had a gap in care from
  Relevant Past Medical History 
1987 – HIV infecon diagnosis  
1999 – iniaon of anretroviral therapy 
2003 – worsening of renal funcon (eGFR<30 mL/min/1.73 m2) 
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since 2007 – undetectable HIV viral load 
HCV infecon diagnosis May 1997 
HCV RNA viral load = 536 000 IU/mla  April 2000 
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Gap in care 
Liver transient elastography showed 
F2 ﬁbrosis (sﬀness, 8.2 kPa) 
April 2015 
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April 2017 
Iniaon of HCV treatment: 
sofosbuvir/velpatasvir  (400mg/100mg) 
once daily; given aer dialysis on dialysis 
days 
10th July 2017 HCV RNA viral load = 320 798 IU/mlb  
HCV RNA viral load <12 IU/mlb  31
st July 2017 
24th Sept 2017 End of HCV treatment;   
HCV RNA viral load <10 IU/mlc  
4th Oct 2017 Undetectable  HCV RNAb
18th Dec 2017 Undetectable  HCV RNAc  
Paent is successfully treated and cured 
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Figure 1. The timeline summary of the case. HCV=hepatitis C virus, HIV=human immunodeﬁciency virus, RNA= ribonucleic acid. aCobas Amplicor HCV Monitor
test, v2.0, Roche Switzerland, bAbbott RealTime HCV assay, cXpert HCV Viral Load.
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a combination of stavudine, lamivudine and lopinavir/ritonavir.
The patient became fully compliant with his ART in October
2006 and since July 2007 had an undetectable HIV viral load on
all occasions (measurements were done 2 to 3 times per year).2The patients’ past history included treatment with steroids for
immune thrombocytopenia in 2000, avascular necrosis of the left
hip (hip replacement was done in 2007 and 2016) and secondary
hyperparathyroidism for which he underwent subtotal parathy-
roidectomy in 2015.
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the modiﬁcation of diet in renal disease equation was normal up
to January 1998 (111.9mL/min/1.73m2). It gradually worsened
and became < 30mL/min/1.73m2) in May 2003. The patient
started chronic dialysis in January 2005. He had no history
of substance abuse nor was he ever treated for substance
dependence. The liver function tests (aspartate and alanine
aminotransferases) were within normal limits throughout the
years of follow-up. Liver transient elastography (FibroScan)
was done in April 2015 and April 2017 indicating F2 (stiffness,
8.2 kPa) and F3 (stiffness, 11.6 kPa) ﬁbrosis respectively. The
patient has never been treated for HCV infection. It was decided
to commence treatment with a ﬁxed dose combination of once
daily sofosbuvir/velpatasvir (400mg/100mg; Epclusa) on the
10th of July 2017. On dialysis days, Epclusa was given after
dialysis. The patient’s ART at that time was lopinavir/ritonavir
monotherapy. His pretreatment HCV RNA viral load was
320798IU/mL (Abbott RealTime HCV assay). On the ﬁrst
follow-up visit 3-weeks after introduction of anti-HCV therapy
(31st of July 2017) the serum quantitative real time polymerase
chain reaction (PCR) showed <12 IU HCV RNA per mL.
Therapy with sofosbuvir/velpatasvir ended on 24th of September
2017. The total duration of treatment was about 11 weeks since
the patient misinterpreted instruction on how to take the drug
and he took Epclusa twice daily during the ﬁrst week of
treatment. At end of HCV treatment (25th of September 2017)
the HCV RNA quantitative real time PCR showed <10 IU HCV
RNA per mL of serum (Xpert HCV Viral Load, Cepheid,
Sunnyvale, CA) and on a follow up sample (4th of October 2017)
HCV RNA was undetectable (Abbott RealTime HCV assay).
Twelve weeks after treatment cessation (18th of December 2017)
HCV RNA was undetectable (Xpert HCV Viral Load) and the
patient is now considered cured fromHCV infection. The patient
did not report any drug side effects. The timeline summary for
this case is shown on the Figure 1. Written permission to publish
this case report was obtained from the patient.
3. Discussion
Several studies have reported treating HCV infection in patients
with severe renal impairment or on hemodialysis with sofosbuvir-
based regimens with sustained virologic response at 12 weeks
(SVR12) of 80% to 100%.[1–5] Patients with advanced chronic
kidney disease (eGFR 45mL/min/1.73m2) had more frequently
anemia, worsening of renal function and serious adverse effects
than patients with no or less severe renal impairment.[2,5]
Nevertheless, in a report of 62 patients on maintenance dialysis
sofosbuvir was well tolerated and increased use of erythropoietin
was observed only when ribavirin was given.[4] Sofosbuvir is
mainly eliminated by the renal route and plasma concentrations of
its renally excreted metabolite GS-331007 are signiﬁcantly higher
in patients with renal impairment compared to those without.[6]
However, Desnoyer et al[7] reported that sofosbuvir or its inactive
metabolite sofosbuvir-331007 did not accumulate in plasma of
patients on hemodialysis. In HIV/HCV coinfected patients,
sofosbuvir/velpatasvir may be given with most antiretrovirals,
with the exception of efavirenz, etravirine and nevirapine,[8,9] and
Wyles et al reported it was a safe regimen that provided SVR12 in
95% patients with HIV/HCV pan-genotypic coinfection.[10]
Glecaprevir/pribentasvir is a highly efﬁcacious new treatment
option for patients with HCV genotype 3 infection.[11] The
EXPEDITION-4 trial evaluated that regimen in patients with3severe kidney disease or undergoing dialysis who had HCV
genotype 1–6 infection and also had compensated liver disease
and reported an SVR12 rate of 98%.[12] However, glecaprevir/
pribentasvir was not available in Croatia at the time of initiation
of anti-HCV treatment in our patient. Also, cure of HCV-
infection is a prerequisite for kidney transplantation in Croatia.
Although sofosbuvir is not licensed and recommended for use in
patients with severe renal impairment[8] mainly because of safety
concerns[5,8] its use with velpatasvir for genotype 3 infection in
patients on dialysis is an option when other drug combinations
are not available. To our knowledge, this is the ﬁrst report of a
patient with HIV/HCV genotype 3 coinfection undergoing
dialysis, who was successfully treated with sofosbuvir/velpatasvir
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